X
X

Vadodara

Home / Research & Trials / Vadodara

Vadodara
Sl.No Principal Investigator’s Name Study Title Phase Protocol Number Indications Department Study Status Link Contact Person & Contact Details
1 Dr.Pinaki Mahato A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer Phase 3 I3Y-MC-JPCF Breast Cancer Department of Medical Oncology ongoing https://clinicaltrials.gov/ct2/show/NCT03155997 “Shivangi Naik Ph: 9978906225”
2 Dr.Pinaki Mahato Randomized, Assessor-Blind, Multicentre, Parallel Group, Two Arms, Clinical Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Rituximab (Test Product, Zydus) in comparison with Rituximab (Reference Product, Roche/Genentech) in Patients with Diffuse Large B Cell Lymphoma (DLBCL). Phase 3 RITU.17.001 DLBCL Department of Medical Oncology soon to be closed out http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=26813&EncHid=&modid=&compid=%27,%2726813det%27 “Shivangi Naik Ph: 9978906225”
3 Dr.Pinaki Mahato A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) Phase 3 D967RC00001 Berast Cancer Department of Medical Oncology ongoing https://clinicaltrials.gov/ct2/show/NCT05113251 “Shivangi Naik Ph: 9978906225”
4 Dr.Pinaki Mahato A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer. Phase 3 PERT.21.001 Metastatic Breast Cancer Department of Medical Oncology EC approved. SIV soon https://clinicaltrials.gov/ct2/show/NCT05283837 “Shivangi Naik Ph: 9978906225”
5 Dr.Pinaki Mahato A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) Phase 3 D910SC00001 Esophageal Squamous Cell Carcinoma Department of Medical Oncology EC submitted https://clinicaltrials.gov/ct2/show/NCT04550260 “Shivangi Naik Ph: 9978906225”

To get in touch with the Clinical Trials Team at HCG, please call on +91 80 4020 6000 (extn: 6058)

Research and Trials

To know more about facilities available for patients at HCG

HCG Call Icon